Biogen Seeks FDA Approval For Its Once-Doomed Drug For Alzheimer’s
There is reasonable confidence with Biogen CEO Michel Vounatsos about getting the approval for the drugmaker’s experimental Alzheimer’s drug from the United States Food and Drug Administration. “We worked in full transparency with the regulator,” Vounatsos said in a television interview while also emphasizing that all of the data about the drug that the company…









